US Therapeutic Plasma Exchange Market by Product (Reagent, Instruments, Antibodies, Kits, Consumables & Accessories), Type (Direct, Indirect), Disease (Infectious Disease, Other Diseases), End User (Contract Research Organizations) – Global Forecast to 2026" The global US Therapeutic Plasma Exchange market is projected to reach USD 3.5 billion by 2026 from USD 2.6 billion in 2021, at a CAGR of 6.0% during the forecast period. The growth in this market is primarily attributed to the increasing prevalence of chronic diseases and rising R&D spending & healthcare expenditure. Emerging markets are expected to provide growth opportunities for players operating in the US Therapeutic Plasma Exchange market in the coming years.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=87153046

Browse in-depth TOC on "US Therapeutic Plasma Exchange Market”

50 – Tables

33 – Figures

133 – Pages

By product, the consumables segment is expected to account for the largest share of the US therapeutic plasma exchange market

Based on products, the US therapeutic plasma exchange market is segmented into devices and consumables. The consumables segment accounted for the largest share of the US therapeutic plasma exchange market. The large share of this segment can be attributed to the recurrent use of these products, the increasing number of therapeutic plasma exchange procedures, and favorable reimbursement policies for TPE procedures.

By technology, the centrifugation technology segment is expected to register the highest CAGR during the forecast period.

On the basis of technology, the US therapeutic plasma exchange market has been segmented into centrifugation and membrane separation. The centrifugation technology segment is expected to register the highest CAGR during the forecast period. The highest rate of this segment can be attributed to the advantages offered by centrifugation over membrane separation, such as high efficiency and its ability to separate all types of blood components

By indication, the neurological disorders segment accounted for the largest share of the US therapeutic plasma exchange market.

On the basis of indication, the US therapeutic plasma exchange market has been segmented into neurological disorders, renal disorders, hematologic disorders, metabolic disorders, and other indications. In 2019, the neurological disorders segment accounted for the largest share of the US therapeutic plasma exchange market. Growth in this market is majorly driven by the rising prevalence and incidence of neurological diseases in the geriatric population, increasing awareness about the treatment of neurological diseases using plasma exchange, and rising investments by key players for R&D on the new application areas of therapeutic plasma exchange in the treatment of neurological disorders.

On the basis of end user, the hospitals and transfusion centers segment is estimated to grow at the highest CAGR during the forecast period.

Based on end users, the US therapeutic plasma exchange market has been segmented into blood collection centers and blood component providers, hospitals and transfusion centers, and other end users. The hospitals and transfusion centers segment is estimated to grow at the highest CAGR during the forecast period. The high growth of this segment can be attributed to the increasing adoption of therapeutic apheresis in the treatment of various diseases, growing indications of therapeutic apheresis, and rising awareness of apheresis as a therapy.

Request Sample Pages:https://www.marketsandmarkets.com/requestsampleNew.asp?id=87153046

Key Market Players

The prominent players in the US therapeutic plasma exchange market Terumo BCT, Inc. (US), Fresenius SE & Co. KGaA (Germany), Haemonetics Corporation (US), Asahi Kasei Medical Co. Ltd. (Japan), B. Braun Melsungen AG (Germany), Baxter International Inc. (US), Cerus Corporation (US), Kaneka Corporation (Japan), Kawasumi Laboratories, Inc. (Japan), Nikkiso Co., Ltd. (Japan), Miltenyi Biotec (Germany), Medica S.p.A. (Italy), Medicap Clinic GmbH (Germany), and Infomed (Switzerland).

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=87153046

 

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their pain points around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 Micro Quadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.

630 Dundee Road

Suite 430

Northbrook, IL 60062

USA: +1-888-600-6441

Email: [email protected]

Research Insights: https://www.marketsandmarkets.com/ResearchInsight/fluid-management-visualization-systems-market.asp

Visit Our Website: https://www.marketsandmarkets.com/

Content Source: https://www.marketsandmarkets.com/PressReleases/immunofluorescence-assay.asp